Washington Trust Bancorp, Inc. (WASH) Forms $52.90 Double Top; Summit Therapeutics plc (SMMT) Had 6 Analysts Last Week

Washington Trust Bancorp, Inc. (WASH) formed double top with $57.13 target or 8.00% above today’s $52.90 share price. Washington Trust Bancorp, Inc. (WASH) has $911.31M valuation. The stock increased 1.54% or $0.8 during the last trading session, reaching $52.9. About 42,186 shares traded or 19.58% up from the average. Washington Trust Bancorp, Inc. (NASDAQ:WASH) has risen 30.56% since February 10, 2017 and is uptrending. It has outperformed by 13.86% the S&P500.

Among 7 analysts covering Summit Therapeutic (NASDAQ:SMMT), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Summit Therapeutic had 11 analyst reports since August 19, 2015 according to SRatingsIntel. H.C. Wainwright reinitiated Summit Therapeutics plc (NASDAQ:SMMT) on Friday, December 1 with “Buy” rating. Oppenheimer maintained Summit Therapeutics plc (NASDAQ:SMMT) rating on Wednesday, August 19. Oppenheimer has “Buy” rating and $28 target. Canaccord Genuity maintained the stock with “Buy” rating in Thursday, June 15 report. The rating was maintained by RBC Capital Markets on Wednesday, November 16 with “Outperform”. The company was initiated on Tuesday, June 21 by Janney Capital. H.C. Wainwright maintained Summit Therapeutics plc (NASDAQ:SMMT) on Thursday, July 6 with “Buy” rating. As per Friday, January 26, the company rating was maintained by Oppenheimer. Zacks downgraded Summit Therapeutics plc (NASDAQ:SMMT) on Tuesday, September 1 to “Hold” rating. The stock of Summit Therapeutics plc (NASDAQ:SMMT) earned “Buy” rating by H.C. Wainwright on Friday, September 16. Oppenheimer maintained the shares of SMMT in report on Thursday, June 22 with “Buy” rating. See Summit Therapeutics plc (NASDAQ:SMMT) latest ratings:

26/01/2018 Broker: Oppenheimer Old Rating: Outperform New Rating: Outperform Old Target: $24 New Target: $30 Maintain
04/01/2018 Broker: SunTrust Rating: Buy New Target: $24 Initiates Coverage On
01/12/2017 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy New Target: $16 Reinitiate

Among 4 analysts covering Washington Trust Bancorp (NASDAQ:WASH), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Washington Trust Bancorp has $59.0 highest and $39.0 lowest target. $45.20’s average target is -14.56% below currents $52.9 stock price. Washington Trust Bancorp had 16 analyst reports since July 22, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Keefe Bruyette & Woods on Wednesday, December 30. The stock of Washington Trust Bancorp, Inc. (NASDAQ:WASH) has “Neutral” rating given on Tuesday, September 20 by Compass Point. The firm has “Hold” rating given on Thursday, December 21 by Keefe Bruyette & Woods. Compass Point maintained it with “Neutral” rating and $39.0 target in Tuesday, October 20 report. As per Friday, May 26, the company rating was maintained by Keefe Bruyette & Woods. The rating was upgraded by Compass Point on Wednesday, January 27 to “Buy”. The company was upgraded on Thursday, January 26 by Compass Point. The firm has “Hold” rating by Keefe Bruyette & Woods given on Tuesday, September 26. Compass Point downgraded Washington Trust Bancorp, Inc. (NASDAQ:WASH) on Tuesday, October 24 to “Hold” rating. On Friday, November 18 the stock rating was downgraded by Compass Point to “Neutral”.

Since September 11, 2017, it had 0 insider purchases, and 3 selling transactions for $172,976 activity. ALGIERE DENNIS L sold $53,772 worth of stock. Noons Mary E. had sold 129 shares worth $6,579. 2,000 shares were sold by HOXSIE KATHERINE W, worth $112,625 on Thursday, October 26.

Investors sentiment increased to 1.31 in Q3 2017. Its up 0.15, from 1.16 in 2017Q2. It improved, as 7 investors sold Washington Trust Bancorp, Inc. shares while 28 reduced holdings. 15 funds opened positions while 31 raised stakes. 9.43 million shares or 0.20% less from 9.45 million shares in 2017Q2 were reported. Franklin Res Inc stated it has 0.01% of its portfolio in Washington Trust Bancorp, Inc. (NASDAQ:WASH). Alliancebernstein L P, New York-based fund reported 24,015 shares. Systematic Fincl Ltd Partnership has invested 0.18% in Washington Trust Bancorp, Inc. (NASDAQ:WASH). Metropolitan Life Com Ny has 11,067 shares for 0% of their portfolio. Advisory Networks Ltd Liability Corporation has 0% invested in Washington Trust Bancorp, Inc. (NASDAQ:WASH). Endurance Wealth Management holds 106,882 shares or 1.01% of its portfolio. Parsons Capital Mgmt Incorporated Ri stated it has 0.09% of its portfolio in Washington Trust Bancorp, Inc. (NASDAQ:WASH). 1,871 are owned by Great West Life Assurance Can. Voya Mngmt Lc stated it has 10,277 shares. Evercore Wealth Management Llc holds 12,853 shares. The Florida-based State Board Of Administration Of Florida Retirement Systems has invested 0% in Washington Trust Bancorp, Inc. (NASDAQ:WASH). Foundry Ptnrs Limited Co holds 0.19% or 81,370 shares in its portfolio. Brown Brothers Harriman has 0% invested in Washington Trust Bancorp, Inc. (NASDAQ:WASH). Citadel Advisors Limited Liability Com holds 0% or 5,329 shares. Sei Investments has 218 shares for 0% of their portfolio.

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. The company has market cap of $151.11 million. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection (CDI). It currently has negative earnings. The companyÂ’s lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial in patients with DMD; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials for the treatment of CDI disease.

The stock decreased 6.28% or $0.71 during the last trading session, reaching $10.6. About 135,963 shares traded or 70.95% up from the average. Summit Therapeutics plc (NASDAQ:SMMT) has risen 33.22% since February 10, 2017 and is uptrending. It has outperformed by 16.52% the S&P500.